Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. has convened its 2025 annual general meeting for June 16, 2026 in Yantai, where shareholders will review the board’s work report, financial statements, full annual report and profit distribution plan for 2025, as well as decide on the reappointment of domestic and foreign auditors and confirm directors’ remuneration. These items will shape the company’s capital allocation, governance practices and assurance framework for the coming year.
Shareholders will also vote on granting a general mandate to issue additional shares, changing the registered capital, amending the Articles of Association, revising key internal management policies, adjusting certain A-share proceeds-funded projects and electing the third session board directors, including several executive and non-executive members. The proposed changes could affect RemeGen’s capital structure, internal controls and strategic use of fundraising, while the refreshed board composition may influence future strategic direction and oversight for stakeholders.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates from its facilities in Yantai, Shandong Pilot Free Trade Zone, and is engaged in drug research, development and commercialization, serving domestic and international healthcare markets.
Average Trading Volume: 4,229,589
Technical Sentiment Signal: Buy
Current Market Cap: HK$63.37B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.